NCT06232629 is a NA clinical trial of TUS Active in Parkinson Disease, sponsored by University Health Network, Toronto.

Who is sponsoring NCT06232629?

NCT06232629 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT06232629?

Interventions in NCT06232629: TUS Active, TUS Sham.

What condition does NCT06232629 study?

NCT06232629 studies Parkinson Disease, Dystonia.

Is NCT06232629 still recruiting?

NCT06232629 is currently active, enrolled. Last updated 15 September 2025.

Last reviewed 2025-09-15 · How we verify

NCT06232629

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Towards Noninvasive DBS of the Basal Ganglia in Parkinson's Disease Using TUS

Active, enrolled NA Last updated 15 September 2025

What this trial tests

NA trial testing TUS Active in Parkinson Disease in 10 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 August 2023

Primary endpoint
31 December 2025

31 December 2026

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	10
Start date	1 August 2023
Primary completion	31 December 2025
Estimated completion	31 December 2026
Sites	1 location across Canada

Drugs / interventions tested

TUS Active
TUS Sham

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →
Dystonia — all drugs for Dystonia →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Parkinson Disease or Dystonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Transcranial Ultrasound Stimulation (TUS) is an emerging non-invasive brain stimulation technique capable of targeting both superficial and deep brain areas with high spatial resolution, down to a few cubic millimeters. In this study, the investigators aim to use TUS to non-invasively modulate the globus pallidus internus (GPi) in patients with Parkinson's disease (PD) and dystonia. These patients have previously been implanted with deep brain stimulation (DBS) leads. The investigators plan to simultaneously record local field potentials (LFPs) from the DBS leads using the Percept PC device (Medtronic Inc.) while the DBS is turned off. The study's goal is to investigate the mechanism of action of TUS and its neuromodulatory effects on LFPs recorded from the GPi. This will enable us to compare the effects of TUS with those of DBS.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Individualized non-invasive deep brain stimulation of the basal ganglia using transcranial ultrasound stimulation.
Darmani G, Ramezanpour H, Sarica C, Annirood R, et al · · 2025 · cited 31× · PMID 40108143 · DOI 10.1038/s41467-025-57883-7
Current state of clinical ultrasound neuromodulation.
Matt E, Radjenovic S, Mitterwallner M, Beisteiner R. · · 2024 · cited 27× · PMID 38962179 · DOI 10.3389/fnins.2024.1420255

Verify or expand the search:

Other trials of TUS Active

Trials testing the same drug.

NCT05965960 — Investigating LFP Correlates of TUS in Patients With Movement Disorders · NA · unknown

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06232629 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 15 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06232629.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing